Bosutinib waa Src / Abl dual tyrosine kinase inhibitor loo ogolaaday daawaynta wajiga cusub ee dabadheeraad ah (CP) chronic myelogenous leukemia (CML), ama adkaysi ama dulqaad la'aan daawaynta hore CML. Daraasadu waxay isbarbar dhigtay xogta laga helay besutinib-ka koowaad iyo daawaynta imatinib ee ≥24 bilood oo dabagal ah. BFORE waa mid socota, sumadda furan wajiga III daraasad caafimaad oo leh wadar ahaan 536 bukaan oo diiwaangashan oo si aan kala sooc lahayn loogu qoondeeyay inay helaan bursatinib (n = 268) ama imatinib (n = 268) ee 1: 1 daaweynta saamiga.
At a follow-up of 12 months, compared with the imatinib group, the bosutinib group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). Farqigaasina wuxuu sii waday dabagalka 24 bilood kadib. 24 bilood oo dabagal ah, labada koox waxay muujiyeen farqi weyn oo u dhexeeya (MMR), laakiin farqiga u dhexeeya MR4 iyo MR4.5 muhiim ma ahayn. Marka loo barbardhigo kooxda imatinib, waqtiga lagu gaarayo MR iyo CCyR wuu ka gaabiyey kooxda bosutinib. Lix bukaan oo ka tirsan kooxda bosutinib iyo toddobo bukaan oo ka tirsan kooxda imatinib ayaa loo beddelay wejiga degdega / degdegga ah. Bilaha 24 ee dabagalka, marka la barbardhigo kooxda imatinib, kooxda bosutinib waxay muujisay cafis weyn oo dhanka molecular ah (MMR). Daraasaduhu waxay taageeraan isticmaalka bosutinib ee daaweynta-safka koowaad ee bukaanka CP CML.
